Intake of Bifidobacterium, can also improve the response to ICIs against PD-L1 target and modify the TME for HCC, as well as in melanoma [54], while intake of Firmicutes and Faecalibacterium supplements can enhance the response of monoclonal antibodies against CTLA-4, such as ipilimumab, as it was reported also in melanoma cases. This evidence concerns the gene CD274 and hepatocellular carcinoma.